Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference - KTRE.com | Lufkin and Nacogdoches, Texas

Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference

Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.

SOURCE Keryx Biopharmaceuticals, Inc.

Presentation Scheduled for Monday, March 18th at 10:00 AM PT

NEW YORK, March 14, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the upcoming 25th Annual ROTH Conference, to be held March 17th -20th in Dana Point, California.  Mr. Bentsur's presentation is scheduled to take place on Monday, March 18th, at 10:00 AM PT (1:00 PM ET). 

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Keryx has completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA, and Keryx expects to submit a New Drug Application with the FDA in the second quarter of 2013 and a Marketing Authorization Application with the EMA in mid-2013.  Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stages 3 to 5 non-dialysis dependent chronic kidney disease.  In addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease.  Keryx is headquartered in New York City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

©2012 PR Newswire. All Rights Reserved.

  • KTRE.com RSS News Feeds RSS (Really Simple Syndication) is an easy way for you to keep up with all of your favorite news and information.
    KTRE.com RSS News Feeds RSS (Really Simple Syndication) is an easy way for you to keep up with all of your favorite news and information. An RSS feed contains headlines and links to full news stories
  • The StormTracker 9 Weather mobile app offers interactive radar, video and text forecasts, alerts and much more to help you plan your day and to be on alert for severe weather.
    The StormTracker 9 Weather mobile app offers interactive radar, video and text forecasts, alerts, and much more to help you plan your day and to be on alert for severe weather.
  • Curious about East Texas Weather? Want to get the latest weather stories? Check out the weather blog. You never know what a meteorologist is thinking!
    Curious about East Texas Weather? Want to get the latest weather stories? Check out the weather blog. You never know what a meteorologist is thinking!